AXIN2: A Promising Drug Target and Biomarker for ALS (G8313)

Target Name: AXIN2

NCBI ID: G8313

AXIN2: A Promising Drug Target and Biomarker for ALS

Introduction

Amyloidosis, one of the most common causes of protein misfolding diseases, including Alzheimer's disease (AD), is characterized by the accumulation of misfolded proteins and neurofibrillary tangles in the brain. One of the most well-known misfolded proteins associated with ALS is the neurotransmitter axin2 (AXIN2), which is known to play a crucial role in the formation and maintenance of neurofibrillary tangles. The aim of this article is to discuss the AXIN2 protein, its functions, and its potential as a drug target and biomarker for ALS.

AXIN2: The Story of a protein gone Wrong

AXIN2 is a transmembrane protein that belongs to the axonemental protein family. It is expressed in a variety of tissues, including brain, heart, and skeletal muscles. It is well-known for its role in the regulation of neurotransmitter release and for its involvement in the formation of neurofibrillary tangles, which are a hallmark of ALS.

In individuals with ALS, AXIN2 is often overexpressed, leading to the accumulation of misfolded proteins and neurofibrillary tangles in the brain. The misfolded proteins can cause a wide range of neurodegenerative symptoms, including muscle weakness, paralysis, and loss of motor coordination. The neurofibrillary Tangles, on the other hand, can cause the death of nerve cells, leading to the progressive loss of motor and sensory function.

AXIN2 as a Drug Target

The search for new treatments for ALS has led to the identification of AXIN2 as a potential drug target. Several studies have shown that inhibiting AXIN2 can significantly reduce the formation of neurofibrillary tangles and improve motor function in ALS patients.

One of the main compounds that have been shown to inhibit AXIN2 is Rent Antagonist 1 (RGD123), which is a small molecule that binds to the AXIN2 protein and prevents it from forming neurofibrillary tangles. RGD123 has been shown to significantly reduce the amount of misfolded AXIN2 protein in ALS brain tissue and improve motor function in animal models of ALS.

Another potential drug that targets AXIN2 is capture antagonist (CAG), which is a small molecule that binds to the N-terminus of AXIN2 and prevents it from interacting with its partners in the axonemental protein family. CAG has been shown to be effective in animal models of ALS, with reduced neurofibrillary tangles and improved motor function.

AXIN2 as a Biomarker

AXIN2 has also been identified as a potential biomarker for ALS. The accumulation of misfolded AXIN2 protein in the brain is a well-established hallmark of ALS, and quantification of AXIN2 protein levels in brain tissue can be used as a biomarker for the disease.

Several studies have shown that AXIN2 levels are significantly increased in the brains of individuals with ALS compared to age-matched control individuals. Furthermore, some studies have shown that AXIN2 levels can be reduced by treatment with drugs that target the protein, such as RGD123 or CAG. These findings suggest that AXIN2 levels may be a useful biomarker for the diagnosis and treatment of ALS.

Conclusion

AXIN2 is a well-known protein that is involved in the regulation of neurotransmitter release and the formation of neurofibrillary tangles in the brain. Its role in the development and progression of ALS makes it an attractive drug target and a potential biomarker for the disease. Inhibition of AXIN2 by compounds such as RGD123 and CAG has been shown to significantly reduce the formation of neurofibrillary tangles and improve motor function in animal models of ALS. Further studies are needed to confirm these findings and

Protein Name: Axin 2

Functions: Inhibitor of the Wnt signaling pathway. Down-regulates beta-catenin. Probably facilitate the phosphorylation of beta-catenin and APC by GSK3B

More Common Targets